Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $980
Benzinga Newsdesk 8 hours ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $795 to $980.
Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $795 to $980.